AnodyneWiki

Tranylcypromine

Tranylcypromine
Tranylcypromine
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass133.19 g/mol [1]
AppearanceLiquid [1]
Melting point79-80 °C at 1.50E+00 mm Hg [1]
Boiling point79-80 °C @ 1.5-1.6 mm Hg [1]
Solubility48600 mg/L [1]
Predicted LogP1.5 [1]
Structural Identifiers
[]
Molecular formulaC9H11N
IUPAC name2-phenylcyclopropan-1-amine
SMILESC1C(C1N)C2=CC=CC=C2
InChIInChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2
InChIKeyAELCINSCMGFISI-UHFFFAOYSA-N
CAS number155-09-9
PubChem CID5530
Pharmacokinetics[]
Elimination half-life2.5 hours
MetabolismLiver[2][3]
ExcretionUrine, Feces
Routes of administrationOral

Tranylcypromine (also known as dl-Tranylcypromine, Transamine, Racemic Tranylcypromine, Jatrosom, Parnitene, Skf 385, Tranilcipromina, Tranylcyprominum, Cyclopropanamine, 2-phenyl-, trans-(+-)- or Cyclopropylamine, 2-phenyl-, trans-(+-)-) is a monoamine oxidase inhibitor substance of the amphetamine and phenylcyclopropylamine class.

Chemistry

 []

Tranylcypromine is a racemic mixture of the .

Tranylcypromine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target6 (6 contraindicated)

Medical side effects []

76 side effects listed on drug labels in (tranylcypromine).

  • Ataxia
  • Confusional state
  • Feeling abnormal
  • Acne cystic
  • Morphoea
  • Pollakiuria
  • Urinary incontinence
  • Urticaria
  • Akinesia
  • Disorientation
  • Amnesia
  • Abdominal pain
  • Gastrointestinal pain
  • Agranulocytosis
  • Alopecia
  • Anaemia
  • Decreased appetite
  • Anxiety
  • Asthenia
  • Constipation
  • Diarrhoea
  • Dizziness
  • Syncope
  • Somnolence
  • Oedema
  • Dermatitis
  • Rash
  • Body temperature increased
  • Flushing
  • Headache
  • Occipital headache
  • Frequent headaches
  • Blood disorder
  • Haemorrhage
  • Haemoglobin
  • Hepatitis
  • Hypertensive crisis
  • Hypotension
  • Hypotensive
  • Inappropriate antidiuretic hormone secretion
  • Leukopenia
  • Mydriasis
  • Myoclonus
  • Nausea
  • Hypoaesthesia
  • Sensory loss
  • Pain
  • Pallor
  • Palpitations
  • Paraesthesia
  • Muscle spasms
  • Subarachnoid haemorrhage
  • Hyperhidrosis
  • Shock
  • Loss of consciousness
  • Tachycardia
  • Thrombocytopenia
  • Tinnitus
  • Tremor
  • Vomiting
  • Dry mouth
  • Urinary retention
  • Chills
  • Agitation
  • Musculoskeletal stiffness
  • Stiffness
  • Nuchal rigidity
  • Haemorrhage intracranial
  • Hypertension
  • Hypertensive
  • Tenderness
  • Erectile dysfunction
  • Vision blurred
  • Bradycardia
  • Blood pressure increased
  • Insomnia

Indications

  • Agitation
  • Bradypsychic response
  • Cerebration impaired
  • Decreased interest
  • Depressive disorder
  • Dysphoria
  • Fatigability
  • Feeling guilty
  • Major depressive disorder, single episode
  • Melancholia
  • Sexual dysfunction
  • Suicidal ideation

 []

  • Australia: Tranylcypromine is a Schedule 4.[4]
  • Brazil: Tranylcypromine is a C1.[5]
  • Canada: Tranylcypromine is Prescription only.
  • United Kingdom: Tranylcypromine is Prescription only.
  • United States: Tranylcypromine is Prescription only.
  • Other: Tranylcypromine is a Rx-only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5530, Tranylcypromine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5530
  2. Tranylcypromine. Drugbank.ca. https://www.drugbank.ca/drugs/DB00752
  3. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cellular and Molecular Neurobiology. June 1999; 19(3):411–26. PMID 10319194. https://doi.org/10.1023/a:1006901900106
  4. TRANYLCYPROMINE ASP (MedTAS Pty Ltd). Tga.gov.au. https://www.tga.gov.au/resources/prescription-medicines-registrations/tranylcypromine-asp-medtas-pty-ltd
  5. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 12:01:50
drugspromissing (no DrugsPRO reagent data)2026-11-20 12:01:46
erowidmissing (no Erowid substance of that name)2026-11-20 12:01:46
gsrsmissing (no UNII)2026-11-20 12:01:46
hmdbmissing (hmdb.ca refused automated access to HMDB0243563)2026-11-20 12:01:46
keggok2026-11-20 12:01:49
pubchemok2026-11-20 12:01:45
redditmissing (no r/tripreports posts mention it)2026-11-20 12:01:46
siderok2026-11-20 12:01:46
structureok2026-11-20 12:01:46
wikipediaok2026-11-20 12:01:46